Just Part of Frank's Story

careers-1

PixarBio Corporation to Attend and Discuss NeuroRelease™ a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 BIO CEO & Investor Conference in NYC, NY, February 13-14, 2017

Cambridge, Massachusetts (February 13, 2017): PixarBio Corporation (OTC: PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in late 2018 for our 14-day post-surgical pain treatment, announced today that it will be attending the BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City, NY, from February 13 – 14, 2017.

PixarBio Corporation Securities Temporarily Suspended From Trading By The Securities and Exchange Commission

Cambridge, Massachusetts (January 27, 2017): PixarBio Corporation (formerly traded on OTCQX as PXRB) announced today that, pursuant to a January 23, 2017 Order, trading of its securities were temporarily suspended by the Securities and Exchange Commission. The suspension is scheduled to last from January 23, 2017 through February 3, 2017 at 11:59 PM. PixarBio is …

PixarBio Corporation CEO Frank Reynolds to Present NeuroRelease™ a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 NobleCon13 Investor Conference in Boca Raton, FL on Monday, January 30, 2017

Cambridge, Massachusetts (January 27, 2017): PixarBio Corporation (formerly traded on OTCQX as PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in late 2018 for our 14-day post-surgical pain treatment, announced today that its Chief Executive Officer and Chief Science Officer Frank Reynolds will present at the NobleCon13 – …

PixarBio Corporation Terminates InVivo Therapeutics Bid

Cambridge, Massachusetts (January 23, 2017): PixarBio Corporation, (OTCQX: PXRB) today announced that we will stay focused on our NeuroRelease Pain platform and continue to drive our non-opiate non addictive morphine replacement to market with FDA approval expected between the end of 2018 and early 2019.

PixarBio Corporation Expands Non-Opiate R&D Portfolio For Pain with Steroid Injections; Collaborates for Clinical cGMP Manufacturing, and Grooms Team For Clinical Studies of NeuroRelease Post-Surgical Pain Treatments 14-Day, 7-Day, and 3-Day

Cambridge, Massachusetts (January 9, 2017): PixarBio Corporation, (OTCQX: PXRB) today announced the expansion of their non-opiate R&D pain portfolio beyond NeuroRelease to include steroid based injections that can treat acute and chronic pain for up to 90-days. The treatment can be re-injected so it has the potential to be a new option for the treatment of chronic pain.

PixarBio Corporation Entered into an Agreement with Henry Sargent, to Sell to Him all of the Membership Interests in PixarBio’s Wholly Owned Subsidiary Buddhi Mat LLC

Cambridge, Massachusetts (January 5, 2017): PixarBio Corporation, (OTCQX: PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opiod, non-addictive pain treatment with FDA approval expected in early 2019, announced today, that on Friday, December 30, 2016, it sold to Henry Sargent all of the membership interests in Buddhi Mat LLC, the Company’s wholly owned subsidiary.